In addition, minimum Scr during admission used as baseline Scr in recipients with no Scr within 120 days prior to admission or within 150 days from transplant may not reflect baseline Scr as it could be elevated due to AKI prior to admission, there is no information about the exact timing of maximum Scr during admission, rejection, use of erythropoietin stimulating agents, admissions to other hospitals, transplant loss, renal replacement therapy or recovery from AKI, mortality (death with a functioning graft) and death-censored graft loss. This evidence concerns the gene EPO and acute kidney injury.